The pharmaceutical industry is undergoing a profound transformation driven by advancements in Information Technology (IT), with Enterprise Resource Planning (ERP) systems playing a pivotal role in reshaping operations. These systems offer integrated solutions that streamline key business processes, such as production, inventory management, supply chain optimization, regulatory compliance, and data integration, contributing significantly to operational efficiency and organizational agility. This paper explores the evolution and impact of ERP systems within the pharmaceutical sector, highlighting their contributions to overcoming the industry’s inherent challenges, including complex regulatory requirements, the need for accurate and real-time data, and the demand for supply chain resilience. The integration of cloud-based ERP solutions, the incorporation of emerging technologies like Artificial Intelligence (AI), Machine Learning (ML), and the Internet of Things (IoT), and enhanced data analytics capabilities have revolutionized pharmaceutical IT. These advancements not only reduce operational costs, improve forecasting accuracy, and enhance collaboration but also ensure compliance with stringent global regulations, such as Good Manufacturing Practices (GMP) and FDA guidelines. Moreover, ERP systems have been instrumental in managing the pharmaceutical supply chain, ensuring product traceability, and improving inventory control and order fulfillment processes. This manuscript examines how ERP systems enable pharmaceutical companies to maintain high standards of product quality, improve decision-making, and ensure the safety and efficacy of drugs through robust tracking and auditing mechanisms. A case study of a pharmaceutical company that implemented an ERP system demonstrates the tangible benefits, including increased operational efficiency, improved compliance rates, and enhanced customer satisfaction. However, despite the clear advantages, challenges such as customization complexities, data integration issues, and resistance to change remain. As the pharmaceutical industry continues to evolve, ERP systems will remain a cornerstone of digital transformation, facilitating smarter decision-making, better resource management, and enhanced collaboration across global operations. This paper also identifies future trends, including the potential of AI and blockchain technologies in further strengthening ERP systems and transforming the pharmaceutical landscape.

In today’s world of a globalized economy and ubiquitous digital transactions, businesses are hungry for ways to increase transaction efficiency and security. In the real economy, solutions that scale to fit transaction volume or velocity are equally valuable. This is true for clearing and settlement and for the day-to-day needs of buyers and sellers alike. Clever observers of both cash and digital transactions can spot cases where technology that supports transaction security or safety can strengthen consumer-borrower ties, mitigate default risks, and reduce recidivism. In general, a cloud solution for payment processing and merchant services solves two major barriers to optimum business technology: lack of scalability and lack of security [1]. The extension of current practice has its advantages, but new solutions unlock significant opportunities for both consumers and financial institutions [2]. The focus of this work is on the provisioning of cloud-based payment processing and merchant services to financial institutions and established global organizations, although the options available with these services mean they are potentially applicable to a wide range of group entities, including non-trading organizations, pension administrators, and group treasurers. With the increased attention to cybersecurity, a mass of data is available to assist the IT departments of the major payment processors, merchants, and acquirers to get cybersecurity on the radar of C-level executives [3]. The case is put forward for the increased targeting of and reporting to the Board’s Audit, Risk, and Liability Committees of publicly held payment processors and merchants to reduce fraud losses and mitigate the reputation and class action lawsuit risk due to data breaches. The progress of technology in the payment sector requires all stakeholders to have a collective approach in order to mitigate fraud and cybersecurity-related risks in new products and services to enhance consumer confidence and the proportion of retail cashless transactions [4].

The pharmaceutical supply chain has become increasingly complex and vulnerable to various risks, including counterfeit drugs, diversion, and fraud. As these challenges threaten patient safety and the integrity of global healthcare systems, serialization has emerged as a pivotal innovation in pharmaceutical logistics and regulatory compliance. Serialization involves assigning unique identifiers to individual drug packages, enabling precise tracking and authentication at every stage of the supply chain. This process provides unprecedented transparency, enhances product security, and facilitates real-time monitoring of pharmaceutical products as they move from manufacturers to end consumers. Despite its potential to revolutionize pharmaceutical traceability, the integration of serialization technologies faces numerous obstacles. These include high implementation costs, regulatory inconsistencies across regions, and the technological challenges of managing vast amounts of data. Moreover, the complex, multi-tiered nature of the global supply chain introduces additional risks related to data integrity, cybersecurity, and interoperability between systems. As pharmaceutical companies seek to navigate these challenges, innovations in serialization technology—such as blockchain, artificial intelligence (AI), the Internet of Things (IoT), and radio frequency identification (RFID)—are providing promising solutions to enhance efficiency, reduce fraud, and increase visibility. This manuscript explores both the innovative advancements and the key challenges associated with the integration of serialization in the pharmaceutical supply chain. It delves into the evolving regulatory landscape, highlighting the need for global harmonization of serialization standards, and examines the impact of serialization on securing pharmaceutical distribution networks. Additionally, the paper emphasizes the importance of collaboration among manufacturers, technology providers, and regulatory bodies in overcoming implementation barriers and realizing the full potential of serialization. As the pharmaceutical industry moves towards a more interconnected and data-driven future, serialization promises to play a central role in shaping the next generation of drug safety and supply chain management. By addressing the hurdles to adoption and leveraging emerging technologies, the pharmaceutical sector can create a more secure, transparent, and efficient supply chain that better serves public health and fosters greater trust among consumers and healthcare professionals alike.

The synthesis and optimization of Active Pharmaceutical Ingredients (APIs) is fundamental to pharmaceutical drug development, directly influencing drug efficacy, safety, and cost-effectiveness. Over recent years, significant advancements in synthetic methodologies and manufacturing technologies have transformed API production. This manuscript provides an overview of the latest innovations in API synthesis, focusing on key techniques such as green chemistry, continuous flow chemistry, biocatalysis, and automation. Green chemistry principles, including solvent substitution and catalytic reactions, have enhanced sustainability by reducing waste and energy consumption. Continuous flow chemistry offers improved reaction control, scalability, and safety, while biocatalysis provides an eco-friendly alternative for synthesizing complex and chiral APIs. Additionally, the integration of automation and advanced process control using machine learning and real-time monitoring has optimized production efficiency and consistency. The manuscript also discusses the challenges associated with regulatory compliance and quality assurance, highlighting the role of advanced analytical techniques such as HPLC, NMR, and mass spectrometry in ensuring API purity. Looking ahead, personalized medicine and smart manufacturing technologies, including blockchain for traceability, are expected to drive further innovation in API production. This review concludes by emphasizing the need for continued advancements in sustainability, efficiency, and scalability to meet the evolving demands of the pharmaceutical industry, ultimately enabling the development of safer, more effective, and environmentally responsible medicines.

Pharmaceutical Product serialization aims to assign distinct serial numbers to items within a pharmaceutical supply chain. However, this process faces several security challenges like Theft of valid serial numbers may occur, enabling the labelling of counterfeit products. Therefore, it's essential to ensure the uniqueness of serial numbers can be verified at any point in the product's lifecycle within the supply chain. Intimidatory nodes along the distribution network could corrupt planned changes of custody for products. Ensuring verifiability of compliance with these changes is crucial. Manufacturers and consumers need assurance that perishable goods with expired shelf lives are appropriately discarded. In this paper, we review a product serialization method leveraging blockchain technology to address these security concerns within a multi-party perishable goods supply chain. Blockchains offer potential solutions by providing a secure platform for data sharing in multi-party environments, enhancing security and transparency. Within Blockchain technology, each distribution partner is registered to uphold transparency regarding drug information. The system facilitates real-time transfer of ownership changes, recording them as blocks with date and time stamps. This ensures visibility to all partners in real time, maintaining the authenticity of drugs. This article aims to outline how Blockchain technology benefits the pharmaceutical industry by enhancing traceability and trackability of drugs throughout the entire pharmaceutical supply chain.

The digital drug traceability systems ensure the patient-centric dose, dosage form, and strength delivered to the patient as intended in the supply chain. It helps the digital healthcare platforms securely establish drug information supplied to patients for potential treatments. Therefore, it is important for the global supply chain to explore the number of high-end digital health solutions and drug traceability to create an interactive loop on drug security for patients. This article provides an overview of advanced technologies for digital drug traceability, such as blockchain, that would establish a secure pharmaceutical supply chain for the digital world.

Currently, Drug Counterfeiting is the biggest challenge facing the pharmaceutical industry. They are encountering this threat due to high market demand for the drugs and their profit margin. The lack of data transparency and traceability also lured criminals into the counterfeiting of drugs which, is impacting people’s health and put their life in danger. Through the drug supply chain, a substantial portion of counterfeit drugs are injected and distributed through the healthcare supply chain network, so the supply chain plays a vital role in drug distribution and impacts patient lives. Through digitalization in the healthcare sector, Distributed Ledger Technology (DLT) provides a platform with ground-breaking results by providing a system for drug traceability with consideration of the critical requirements of transparency, privacy, and authenticity without involving any third party. In DLT, each distribution partner is registered to maintain transparency with the drug information. Real-time transfer of information about the change of ownership with date and time in the form of blocks gives visibility to all the partners in real time about the authenticity of drugs. This article will give information about the benefits of Distributed Ledger Technology to the pharmaceutical industry and the traceability of drugs from end-to-end of the pharmaceutical supply chain.

The role of enterprise applications in pharmaceutical industries is driving the digital transformation of various critical processes, and one process benefiting from this innovation is pharmaceutical drug traceability. This industry grapples with challenges like a lack of transparency, difficulties in tracking products, a deficit of trust, and issues related to shipping expired products. To address these concerns, blockchain technology as an enterprise application has been harnessed as a solution. Notably, counterfeit drug prevention emerged as the most prevalent category, aligning with the pharmaceutical industry's primary objective. Blockchain technology is an emerging innovation that is finding enterprise applications in various industries, including healthcare. In the healthcare sector, Blockchain networks are being utilized to securely store and exchange patient data across hospitals, diagnostic laboratories, pharmacies, and medical practitioners. These enterprise applications can effectively identify and mitigate critical errors, including potentially hazardous ones within the realm of healthcare. Consequently, this enterprise technology holds the promise of enhancing the efficiency, security, and transparency of medical data sharing within the healthcare system. Moreover, it offers valuable tools for medical institutions to gain insights and improve the analysis of medical records. It visually represents the diverse capabilities, enablers, and the unified workflow process of Blockchain technology in supporting healthcare on a global scale. Additionally, the paper presents a thorough discussion of fourteen significant applications of Blockchain in healthcare, underscoring its pivotal role in addressing issues like deception in clinical trials.

The pharmaceutical supply chain environment has undergone tremendous change in recent decades due to technology, and this shift is intensifying. One of the main concerns of business practitioners is how to cost-effectively integrate, implement, and manage technologies across the supply chain of an organization. Pharmaceutical organizations that produce, ship, and supply goods have trouble tracking their goods, which makes it easier for counterfeiters to get fake medications into the system. The creation and implementation of a stringent technological system might be a significant step in the arduous battle against the prevalence of fake medications and other healthcare items. In supply chain management, digital technologies have a number of potential advantages. The usage of the Internet of Things in supply chains can make every component visible and create a visible supply chain, making it possible to identify the position and specifications of all the components and materials in the supply chain at any given time.

A Medical devices and pharmaceutical drugs are packaged to maintain their stability and integrity during post-production shipping and storage prior to clinical usage. During delivery and storage, the packaging may come into direct or indirect contact with the drug product or medical device, which may result in chemical interactions between the two. Packaging can be crucial for success, protection, and sale. Like other supermarket items, prescription pharmaceuticals must be packaged in a way that will meet the needs of security and provide speedy packaging, safety, identity, superiority of products, patient safety, and goods superiority. Packaging is a science and an art where many factors are taken into account, starting with the fundamental design and technology used to pack the product without any instability and providing protection, presentation and observance of manufactured goods during transportation, storage, and consumption. In order to keep the drug physiochemical, biological, and chemical stability, packaging professionals create containers that can withstand the pressures that are applied during the supply and shipping processes. Improvements in the analysis of prescription drug development had long been fixated on packaging expertise.

Pharmaceutical drug traceability is a regulatory compliance adopted by most nations in the world. A comprehensive analysis was carried out to explain the benefits of adopting enterprise system for pharmaceutical drug traceability. Counterfeit drugs are medicines that are fake and have been produced using incorrect potency, or incorrect ingredients used to manufacture these drugs. Solving the drug counterfeiting problems by identifying the most effective and innovative technologies for protecting people's health is of essence these days for the world. Drug serialization is essential concept for drug traceability in the pharmaceutical supply chain. Blockchain is the latest stringent technology that makes drug distribution more secure in the supply chain. The blockchain-based drug traceability is a distributed shared data platform that shares information that is irreversible, reliable, responsible, and transparent in the PSC. Blockchain uses two powerful module, Hyperledger Fabric and Besu to satisfy important criteria for medication traceability, such as privacy, trust, transparency, security, authorization and authentication, and scalability. Researchers in Health informatics can use blockchain designs as a useful road map to develop and implement end-to-end pharmaceutical drug traceability in the supply chain to prevent drug counterfeiting. Industrial IoT is also a key component for the pharmaceutical industry. IoT systems in pharmaceutical drug traceability can be beneficial as they are based on automation and computational methodologies.

For conducting advanced analytics initiatives to acquire in-depth data into usage habits, regional access, sales, and promotional success, etc., unique identification of packaged pharmaceuticals will be a fantastic enabler. The main objective of this study is to prevent and reduce the production of erroneous and counterfeit drugs using the enterprise system, which has become a serious threat because it damages the reputation of legitimate drug manufacturers by trying to produce and market placebo medications that are identical to the real thing. Due to federal government procedures and priorities that frequently change over time, the majority of implementation takes time. To achieve compliance with numerous federal regulatory authorities, including drug traceability for patient safety, the pharmaceutical industry must implement a systematic procedure in an ERP environment. The goals would be to guarantee medical drug traceability and provide real-time warnings to supply chain stakeholders and regulatory bodies to maximize the benefit of integrating a drug traceability system into an ERP environment. Additionally, manufacturers are compelled to maintain product costs on the higher side due to a heavy burden of unchecked manufacturing cost spikes. As a result, innovative marketing schemes must be introduced in order to increase the reach to consumers by putting into practice successful strategies.

The Blockchain technology uses different type of database that transact data in blocks and then chained each data blocks. When data fills one block, it is chained the same data onto previous block therefore, all the data blocks are stored in chronological order. The blockchain technology can help to ensure that data in supply chain is reliable, accurate and can be shared with all stakeholders without any manipulation. It makes supply chain more transparent and end-to-end digital visibility of data source. Blockchain is stringent technology which fill the gap between stakeholders by providing transparent unmanipulated and truthful data in supply chain. There are many initiatives has been taken by multiple regulatory bodies with partnering with supply chain stakeholders including pharmaceutical manufacturer, distributors and dispensers. In USA, Food and Drug Administration’s regulatory body Drug Supply Chain Security Act (DSCSA) initi-ated pilot program in 2019 with the partnership of leading pharmaceuticals distributors to au-thenticating saleable returns to distributor from supply chain partners. DSCSA used MediLedger blockchain interoperable technology for process evaluation and it robustness for mitigating risk of drug counterfeiting possibilities in supply chain. The DSCSA found that pilot project was suc-cessful and results were astonishing. Later it was declared that blockchain technology can also be used for meeting DSCSA’s 2023 Act for unit level traceability.

The healthcare access is fundamental rights for every human being. It is Governments responsibility to provide good healthcare services and infrastructure to its citizen. Since last few decades, Government and healthcare industries are struggling to minimize the adverse events impacting people health due to fake medicine. The world health organization also predicted that 4 out of 10 medicines in developing and poor countries are either fake or potentially adulterated. Counterfeit drugs cost billions of dollars deficit to world economy and reduce research and development (R&D) funds allocation from organizations. Stopping counterfeit medicine into supply chain is main challenge for Government and regulatory authorities. The Government and regulatory authorities are now making stringent guidelines to prohibit criminals and counterfeiters to supply fake medicine in markets. Healthcare industry need stringent regulations and secure technologies provide sage and authentic drugs to patients. The FDA has published the 10 years roadmap to implement the drug traceability in United States. The Healthcare Distribution Alliance (HDA) has also mandated to print several barcodes and human readable data in product packaging hierarchy. The FDA is participating in pilot project with leading pharmaceutical drug manufacturer and wholesales to use blockchain technology in interoperable digital network for securing digital traceability data transfer between authorized trading partners.

The unrelenting proliferation of data, entwined with the prevalence of mobile devices, has given birth to an unprecedented growth of information obscured by noise. With the Internet of Things and myriad endpoint devices generating vast volumes of sensitive and critical data, organizations are tasked with extracting actionable intelligence from this deluge. Governments and enterprises alike, even under pressure from regulatory boards, have strived to harness the power of data and leverage it to enhance safety and security, maximize performance, and mitigate risks. However, the adversaries themselves have capitalized on the unequal battle of big data and artificial intelligence to inflict widespread chaos. Therefore, the demand for big data analytics and AI/ML for high-fidelity intelligence, surveillance, and reconnaissance is at its highest. Today, in the cybersecurity realm, the detection of adverse incidents poses substantial challenges due to the sheer variety, volume, and velocity of deep packet inspection data. State-of-the-art detection techniques have fallen short of detecting the latest attacks after a big data breach incident. On the other hand, computational intelligence techniques such as machine learning have reignited the search for solutions for diverse monitoring problems. Recent advancements in AI/ML frameworks have the potential to analyze IoT/edge-generated big data in near real-time and assist risk assessment and mitigation through automated threat detection and modeling in the big data and AI/ML domain. Industry best practices and case studies are examined that endeavor to showcase how big data coupled with AI/ML unlocks new dimensions and capabilities in improved vigilance and monitoring, prediction of adverse incidents, intelligent modeling, and future uncertainty quantification by data resampling correction. All of these avenues lead to enhanced robustness, security, safety, and performance of industrial processes, computing, and infrastructures. A view of the future and how the potential threats due to the misuse of new technologies from bandwidth to IoT/edge, blockchain, AI, quantum, and autonomous fields is discussed. Cybersecurity is again playing out at a pace set by adversaries with low entry barriers and debilitating tools. The need for innovative solutions for defense from the emerging threat landscape, harnessing the power of new technologies and collaboration, is emphasized.

The global pharmaceutical supply chain plays a crucial role in ensuring the timely and safe delivery of medicines to patients worldwide. However, the increasing presence of counterfeit drugs within this supply chain poses a significant and growing risk to public health, patient safety, and the integrity of the pharmaceutical industry. Counterfeit drugs—medications that are fraudulently manufactured, mislabeled, or contain incorrect or harmful ingredients—are a major concern as they can lead to ineffective treatments, adverse health effects, and even death. Despite stringent regulatory frameworks and advanced technological solutions, counterfeit drugs continue to infiltrate legitimate supply chains due to factors such as the complexity of the distribution system, global trade practices, and inadequate enforcement in certain regions. This manuscript explores the primary causes behind the proliferation of counterfeit drugs in pharmaceutical distribution, the associated risks, and the multifaceted approaches required to address this growing threat. It discusses the importance of regulatory measures, including international cooperation and stronger compliance frameworks, as well as the role of emerging technologies like serialization, blockchain, and RFID in ensuring traceability and product authenticity. By focusing on the integration of these technologies, the paper also highlights the potential of innovative solutions to enhance transparency, reduce vulnerabilities, and protect the integrity of pharmaceutical supply chains. Additionally, it emphasizes the importance of public awareness campaigns and collaboration between key stakeholders, including pharmaceutical manufacturers, distributors, regulators, and healthcare providers, in creating a more secure and trustworthy pharmaceutical distribution ecosystem. Through a comprehensive exploration of these strategies, this manuscript aims to provide a roadmap for mitigating the risks posed by counterfeit drugs and ensuring the safety and efficacy of medicines for consumers worldwide.

The current financial services sector is realising considerable changes in its operations due to development in technology and embracing of digital platforms. This evolution is changing the established concepts of business, consumers and channels of delivery of services. Financial services firms are changing the way they work through digital transformation due to developments in technology, changes in customer needs, and an increase in emphasis on sustainability. Understanding the opportunities, risks, and new trends in digital transformation is the focus of this paper. Opportunities include efficient real-time decision-making processes, increased transparency and better process controls, which are balanced by the threats of change management, dubious organization-technology fit, and high implementation costs. The study also examines recent advancements, including the application of machine learning and artificial intelligence, developments in mobile and online banking, integration of blockchain, and increasing focus on security and personalised banking. A literature review yields some findings from different studies on rural financial services, the evolution of the blockchain, drivers of digital transformation, cloud-based learning approaches, and emerging sustainability practices. All of these results suggest that more strategic planning, analytics, and more focus on ensuring that organisational objectives are met with transformations should be pursued. Hence, this research findings add to the existing literature in determining how innovative and digital technologies are likely to transform the financial services sector and advance sustainability.

A Changing World Demands Optimized Health Surveillance Systems – and How Data Engineering Can Help There is a growing urgency to manage the public health and emergency response practices effectively today, in light of complex and emerging health threats. Fortunately, a host of new tools, including big and streaming data sources, methods such as machine learning, new types of hardware like blockchain or secure enclaves, and means of data storage and retrieval, have emerged. But, with these innovations comes a grand challenge: how to blend with, and adapt them to, the traditional public health practices. The long-in-place infrastructures and protocols to protect and ensure the welfare of communities are in need of change, or at least update, to enhance their marked longevity of impact directly on the health outcomes and community wellbeing they were designed to fortify. It is in this vein that the essay is written and composed. The investigation in this essay is to query what, particularly, might be the aspects and influences of the emerging veritable cornucopia of new data engineering frameworks that are either being developed specifically for health surveillance and wellness, or are available to be co opted from devices and services already thriving in the current market and research milieu. Knowing what these ways may be could well aid in molding their uptake and spread, ensuring their beneficial impacts on those communities who stand to gain the most. The essay is divided into several key segments. After this introduction, section two details the research methods. In the section that follows, the maximum health outcome potentials of these novel frameworks are reviewed. Part four of the essay takes a more critical approach, addressing how the success of these methods may be hindered and future research avenues. Lastly, the concluding information suggests some actions to take to aid best suit the implementation of these ways, and suggests some thoughts for further research after the completion of these inquiriestrand [1].